SBIR/STTR Research Award
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
Award amount
$218,588Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- B-MoGen Biotechnologies Inc
- Proposal award date
- 2018-08-06
- Contract end date
- 2019-05-05
- UEI
- Not reported
- Solicitation number
- PA17-302
- Topic code
- 100
Research abstract
Abstract
Cancer immunotherapyparticularly genetically engineered adoptive T cell transferhas shown great potential
for the treatment of cancer patientsThe use of T cells engineered to express a specific T cell receptorTCRsor chimeric antigen receptorCARsto treat cancer has generated durable cures for many cancer patients and
has resulted in the first FDA approved CAR T therapy to treat childhood acute lymphoblastic leukemia inMost gene therapies rely on viral methods to genetically modify human primary cellsHoweverviral delivery
method is expensivepoorly reproducible and associated with several safety concerns including insertion in or
near genes that may cause malignancy and generation of replication competent virusThusnon viral DNA
delivery methodssuch as Sleeping Beauty and piggyBachave been employed to generate CAR T cellsAlthough these non viral delivery methods have the advantage of lower costimmunogenicityand regulatory
considerationsthey have been limited by their low transposition efficiency in primary human hematopoietic cellsIn this applicationwe propose to rationally optimize a recently discovered transposonTcBuster to deliver CARs
to T cellsTo this endwe further enhance our already very active hyperactive mutants of the TcBuster
transposase and optimize the delivery of the transposon into cellsFollowing optimization of the TcBuster
transposon systemwe will combine these improvements with our proprietary methods to transfect T cells
efficiently and safelyand test the immunotherapeutic effectiveness of TcBuster delivered CAR into T cellsThe
successful completion of this project will result in the comprehensive methods to produce CAR T cells delivered
by TcBuster which we will license to pharmaceutical companies to produce highly efficient CAR T
immunotherapyMore broadlythese methods could be expanded beyond immunotherapeutic cancer
applications to various infectious diseases in which gene delivery by TcBuster in T cells could be advantageous
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing